Solna

• An Open-label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First-line Treatment in Participants with Advanced … Ended recruitment
  2022-502122-41-00 5 2021-05-11 Clear cell renal cancer
• An Open-label study comparing 177Lu-PSMA-617 plus Standard of Care vs. Standard of Care in the Treatment of mHSPC Ended recruitment
  2023-507970-42-00 5 2021-03-31 PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)
• A Phase II clinical trial comparing the efficacy of RO7198457 versus watchful waiting in patients with ctDNA positive, resected Stage II (hi … Ended recruitment
  2023-509516-28-00 4 2021-02-22 Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III col
• A study of patients with colorectal cancer that have a genetic abnormality in the BRAF gene taking encorafenib plus cetuximab with or withou … Ended recruitment
  2023-509405-77-00 5 2021-02-16 Colorectal cancer (BRAF V600E-mutant mCRC)
• A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab … Ended recruitment
  2022-500439-35-00 5 2021-02-11 treatment-naive chronic lymphocytic leukemia
• Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants with Advanced NSCLC … Ended recruitment
  2023-507475-21-00 10 2021-01-18 Lung Cancer, Non-Small Cell
• A long-term study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN) Ended recruitment
  2024-514502-31-00 5 2021-01-11 Prurigo Nodularis
• A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended recruitment
  2023-504830-23-00 5 2020-12-16 B-cell Lymphoma
• A study of safety and efficacy of NBI-74788 in Classic Congenital Adrenal Hyperplasia Ended recruitment
  2023-509171-16-00 5 2020-11-23 Classic Congenital Adrenal Hyperplasia (CAH)
• Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Ended recruitment
  2023-504805-35-00 9 2020-10-22 Lymphoma of B-cell origin
• An open study for participants who have been on darolutamide treatment in any other Bayer study Ended recruitment
  2022-502084-38-00 5 2020-10-16 Cancer
• A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended recruitment
  2023-506365-64-00 5 2020-10-16 Deleterious Germline or Somatic Homologous Recombination Repair (HRR)
• POLAR BEAR Ended recruitment
  2022-502887-19-00 5 2020-08-18 Diffuse Large B-Cell Lymphoma
• Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiothera … Ended recruitment
  2022-501973-37-00 5 2020-01-30 Endometrial cancer
• Olaparib in combination with pembrolizumab in HRRm and HRD positive cancer Ended recruitment
  2023-503831-17-00 4 2019-12-23 The treatment of participants with HRRm and/or HRD-positive cancer
• Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study) Ended recruitment
  2022-502604-67-00 10 2019-12-20 Malignant pleural mesothelioma (MPM)
• A randomized double blind, multicenter trial to assess time-interval between cytoreductive surgery and adjuvant chemotherapy after administr … Ended recruitment
  2023-507732-20-00 5 2019-11-29 Advanced epithelial ovarian cancer stage III-IV
• A study to determine whether the addition of Dostarlimab (TSR-042) delays recurrence of advanced endometrial cancer Ended recruitment
  2023-506551-23-00 5 2019-11-21 Recurrent or primary advanced (Stage III or IV) endometrial cancer
• Research study to look at how well the drug concizumab works in your body if you have haemophilia with inhibitors Ended recruitment
  2023-506832-33-00 5 2019-11-06 haemophilia A (HA) with inhibitors and haemophilia B (HB) with inhibit
• This study will facilitate data collection of the long-term outcomes of pediatric subjects who have been treated in clinical trials with dab … Ended recruitment
  2023-509276-42-00 6 2019-10-30 Children and Adolescents with Cancers Harboring V600 mutation.
• A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis Ended recruitment
  2023-504718-31-00 10 2019-10-19 Moderately to Severely Active Ulcerative Colitis
• A trial to learn if different cancer treatment combinations are safe and work in people with advanced non-small cell lung cancer that has mu … Ended recruitment
  2023-504624-25-00 4 2019-09-26 Advanced Non-Small Cell Lung Cancer
• Treatment of severe congenital Brittle bone disease after or before and after birth. Ended recruitment
  2023-504593-38-00 9 2019-08-12 Osteogenesis Imperfecta (OI) type III and severe type IV. Severe type
• Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystecto … Ended recruitment
  2023-504932-16-00 5 2019-06-04 Muscle Invasive Bladder Cancer

Showing 265–288 of 382 trials